Novo Sets Long-Term Targets Ahead of Semaglutide Patent Expirations Yahoo FinanceNovo shares slide as drugmaker lays out post-Wegovy growth strategy cnbc.comNovo Nordisk’s stock tumbles as doubts persist about Ozempic maker’s goals for 2030 MarketWatchNovo’s Lack of Turnaround Details Disappoints, Hitting Shares Bloomberg.comWegovy-maker Novo shares slump as management grilled on pricing, M&A BNN Bloomberg
